EFFICIENCY OF THE DRUG TIVORTIN IN PATIENTS WITH CHRONIC HEART FAILURE AFTER COVID-19

Abstract

Summary: COVID-19 is a respiratory tract infection and a highly contagious disease complicated by pulmonary pneumonia. This disease is especially severe in patients with cardiovascular disease. The disease exacerbates the clinical signs of heart failure due to electrolyte imbalance in the blood through direct damage to the cardiovascular system and damage to the endothelium of the vascular wall. Chronic heart failure affects 10% of the world's population over the age of 70, and in total 15 million suffer from this disease in the world. Of interest is the diversity of epidemiological data in the CIS countries and Uzbekistan. The likelihood of an increase in this indicator after a pandemic, the severe course of this infection in patients with chronic heart failure requires special care and treatment.